AAO 2020: Alimera highlights NEW DAY Study for sustained-release intravitreal implant

November 15, 2020

Video

Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.

Recent Videos

WIO 2024: An educator's perspective on shattering glass ceilings in ophthalmology

Hannah Chiu, MD, FRCSC, highlights some of the early benefits of an AI-operated telephone call system for postoperative patient care at WIO 2024

Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally

ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777